A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
Clinical trial NCT05040568 · COMPLETED
Trial details
- NCT number
- NCT05040568
- Sponsor
- M.D. Anderson Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-28
- Primary completion
- 2026-01-15
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.